News

Soliris Is Safe and Effective in Real-world Use, Small US Study Shows

Soliris (eculizumab) safely and rapidly led to clinical benefits in people with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive, according to data from a small real-world U.S. study. Moreover, most patients discontinued maintenance immunomodulatory treatment. The study, “Safety and outcomes of eculizumab for acetylcholine…

MG Symptoms Weigh on Life Quality, Particularly for Women

People with myasthenia gravis, particularly women, have a high symptom burden that considerably affects their health-related quality of life, but the disease’s human cost is rarely given adequate study, a systematic literature review has found. Symptoms generally eased following treatment and disease remission. Still, there is…

Agreement Reached to Market Efgartigimod in Israel, Europe

Medison Pharma has entered into a pact with the global immunology company Argenx to bring efgartigimod to market in Israel and across several European countries for treating adult patients with generalized myasthenia gravis (gMG). The agreement sets the stage for commercialization of efgartigimod in 14 countries: Hungary, Poland, Czech…

MG at Advanced Stage Follows Thymus Surgery in Older Man

A man developed myasthenia gravis (MG), which quickly progressed to an advanced stage, shortly after surgery to remove a tumor in the thymus gland, according to a report from China. Post-surgical MG is rare and its rapid severity even rarer, its scientists noted, and this man’s  MG diagnosis was more…